Significant and substantial reductions in liver steatosis were observed in seladelpar and liraglutide combination (76%) > seladelpar (57%) > seladelpar and selonsertib combination (51%) > liraglutide (47%) > OCA (38%) while the reduction observed with selonsertib (15%) did not reach statistical significance compared with NASH Vehicle (Supplemental Fig.
← all excerpts
Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
1
—
—